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ABSTRACT  
Glucopyranoside  Derivatives of Ketoprofen  have  been synthesized and evaluated for anti-inflammatory, 
analgesic and ulcerogenic activities. In vivo biological screening in mice and rats indicated that derivatives 
improved analgesic and anti-inflammatory activities with significantly reduced ulcerogenicity compared to 
the parent drug.  
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INTRODUCTION 
The occurrence of gastrointestinal damage (bleeding, ulceration) is probably amongst the most prevalent and 
serious of the side-effects associated with the use of non-steroid anti-inflammatory (NSAI) drugs. Ketoprofen 
is a potent anti-inflammatory drug. Chemically, it is propionic  acid derivative provided as a recemic mixture. 
This non-steroidal and non-narcotic drug is administered systemically (via oral and parenteral route) for the 
control of mild to moderate pain as well as of some postoperative and cancer pain 
1.  It has similar 
pharmacological actions to other drugs in this class such as ibuprofen, fenoprofen and naproxen.  It inhibits 
the synthesis of prostaglandin (PG) by inhibiting the enzyme cyclooxygenase (COX). Administration of this 
non-selective COX inhibitor by oral route causes many gastrointestinal side effects, like nausea, vomiting, 
gastric irritation, peptic ulceration and bleeding that limit its clinical use 
2. PGs are ubiquitous compounds 
that mediate a variety of physiologic and pathologic processes. Under normal physiologic conditions, PGs 
play an essential homeostatic role in cytoprotection of gastric mucosa, hemostasis, renal function, gestation 
and parturition 
3-5.  
It is a well accepted fact that gastrointestinal lesions produced by NSAIDs are due to two different 
mechanisms: (a) direct contact with gastric mucosa through oral dose and (b) systemic effect which may be 
manifested by after intravenous dosing
6. Temporarily masking the acidic group of NSAIDs with a view to 
decrease the gastrointestinal toxicity due to direct injury has been postulated
7-10.  This prompted us to 
synthesize and identify new compounds derived from Ketoprofen and to screen them for analgesic, anti-
inflammatory & ulcerogenic activities. 
 
MATERIALS AND METHODS 
Chemistry 
Melting points were determined by Superfit Melting Point Determination Apparatus in open capillary 
tube and were uncorrected (Table 1). IR spectra were taken on Nujol mulls between salt plates. 
1H-NMR 
spectra were recorded, in CDCl3 solution, on a Bruker Avance II 400 spectrometer. The chemical shift are 
reported in part per million (δ, ppm) downfield from tetramethylsilane, which was used as internal standard. 
Mass spectra were also recorded in CDCl3 solution. 
 
Synthetic procedure (Scheme 1) 
Synthesis of 2, 3, 4, 6-tetra-o-acetyl α-D-Glucopyranosyl Bromide (3) 
  Acetic anhydride (400mL) was placed in a two-necked flask kept in an   
ice-salt bath on a magnetic stirrer.  The  temperature was  maintained  at 4°C±1°C  and  2.4  mL of 60% 
perchloric acid is added drop wise. The reaction mixture was allowed to reach room temperature gradually. 
α-D-Glucose (2) (100g) as dry powder was added in portions, with continuous stirring, the temperature being 
maintained at 30 - 40°C. Red Phosphorus (31g) was added immediately followed by bromine (58mL) drop 
wise, keeping the temperature maintained at 20°C. Water (36mL) was added over a period of half an hour, 
stirring and cooling being continued and the temperature being maintained below 20°C. The reaction mixture 
was allowed to stand for 2 hours at room temperature, then dichloromethane (300mL) was added and then 
filtered. The filtrate was washed twice with iced water. The dichloromethane layer was run in saturated 
solution of NaHCO3  to which was added some crushed ice. After the vigorous evolution of CO2, the 
dichloromethane layer was run into a flask containing 10g of powdered activated silica gel and filtered after 
10min; the solvent was removed by the use of rotary evaporator. The syrupy mass crystallized as a thick 
layer around the inside of the flask. Portions of the solid was transferred to a pestle mortar and ground with a 
2:1 mixture of light petroleum (B.P. 60-80°C) & dry ether. The combined slurry was filtered and washed 
with a light-petroleum ether solvent mixture and then with 50mL of previously chilled (0°C) dry ether.  
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Synthesis of Ketoprofen tetraacetyl ß-D-Glucopyranosyl derivative ( 4) 
To a solution of Ketoprofen (0.61g, 3mmol) and 2, 3, 4, 6-tetra-o-acetyl α-D-glucopyranosyl bromide 
(1.64g, 4mmol) in dichloromethane was added Tetrabutyl ammonium bromide (0.644g, 2mmol) with stirring 
at 5°C. Aqueous sodium hydroxide (10%,10 mL) was added to it drop wise over a period of 30 min and the 
reaction mixture further stirred for 24 hr. The organic layer separated out, was washed with water followed 
by 5% aqueous NaHCO3 solution, again with water. The product was dried and concentrated in vacuo. A 
semi-solid mass so obtained was purified on a column of silica gel and crystallized from ethanol as colourless 
needles. Yield was 81.5%. 
IR (KBr): 2961.6 and 2874.0, 3060.7, 1651.6, 1594.8, 1461.8 and 1381.0 cm
-1 
NMR (CDCl3): 2.01(s, 12H, OCOCH3), 7.31-7.70(m, 9H, aromatic), 3.78(m, 1H,     CH), 1.52(m,  3H,  
CH3), 4.09( s, 2H, CH2) 
Mass: 584.4 (M
+) 
Synthesis of Ketoprofen ß-D-Glucopyranosyl   derivative ( 5)  
            The tetra acetyl derivative was deacetylated by adding 1.45 mL of 0.5% sodium    methoxide solution 
and kept at room temperature for 45 min. The reaction mixture was neutralized with Amberlite IR 120, SD 
fine, filtered and  concentrated in vacuo.  A semi-solid mass so obtained was crystallized from absolute 
ethanol as colourless compound. Yield was 67%. 
      IR (KBr): 3405.8, 2961.6 and 2874.0, 1742.2, 1461.8, 1200.9 cm
-1. 
NMR(CDCl3): 2.0(s, 4H, OH), 7.31-7.70(m, 9H, aromatic), 3.78(m,1H, CH), 1.52(m, 3H, CH3), 
3.79( m,2H,CH2) 
Mass: 416.1 (M
+) 
Anti-inflammatory activity 
Anti-inflammatory activity was determined by Carrageenan induced rat paw edema method. Six male 
Sprague-Dawley rats with a body weight between 100 and 150 g were used for each test and control groups. 
Just before injection of the test compounds the volume of the paw was measured plethysmometrically
11. 
Animals were pretreated intraperitoneally with 1mL of 20mL/kg of either test compounds or ketoprofen 
drug. The control group received the same volume of the vehicle. Edema was induced after one hour by sub 
planter injection of 0.05 mL of a 1% solution of carrageenan into the left hind paw. The increase in paw 
volume was determined 2, 4, 6, 8 and 24 h. The percentage anti-inflammatory activity was calculated by the 
formula: anti-inflammatory activity=(1-dt/dc)/100 where dt is the difference of paw volume in drug/test 
compounds treated groups and dc is the difference in paw volume of the control group. 
 
Analgesic activity 
  Analgesic activity was determined in mice by Tail flick method. 
The prescreened animals (reaction time:3-4 sec) were divided into  control, standard &  test  groups. 
Ketoprofen 20 mg/kg acted as the standard drug. The drugs were administered intraperitoneally. The tail flick 
latency was assessed by the analgesiometer (Inco, India). The strength of the current passing through the 
naked nicrome wire was kept constant at 6 Amps. The distance between the heat source and the tail skin was 
1.5 cm. The site of application of the radiant heat in the tail was maintained at 2.5 cm, measured from the 
root of the tail. The cut-off reaction time was fixed at 10 sec to avoid tissue damage
12.  
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Ulcerogenic activity 
The Albino rats of either sex (100-150g) were fasted for 12 hours. They’re administered orally an 
aqueous suspension of the drug twice a day over a two-day period. The rats were then sacrificed the day after 
giving the final dose. To determine the gastric mucosal damage, rat stomachs were removed, opened along 
the length of greater curvature and cleaned of the debris, washed and examined under a microscope (10x) & 
the ulcers were scored as 
 
0.0  Normal colour stomach 
0.5  Red coloration 
1.0  Spot ulcers  
1.5  Hemorrhagic streaks 
2.0  Ulcers > 3mm but < 5mm 
3.0  Ulcers > 5mm 
The mean ulcer score for each animal was expressed as Ulcer/Lesion Index (LI). 
For assessing the incidence of ulceration, the rats showing ulcers greater than 0.5mm in gastric 
mucosa were considered to have a positive ulcerogenic response
13
1.  Brocks DR and Jamali F. Pharmacokinetics of ketorolac tromethamine, Clin. Pharmacokin. 1992; 23: 
415–427. 
. 
   
RESULTS & DISCUSSION   
The glucopyranoside derivatives were synthesized successfully and evaluated for their analgesic, anti-
inflammatory and gastrointestinal toxicity. They showed improved anti-inflammatory and analgesic activity 
over the parent drug. The test compound 5 showed 64.28 % inhibition in edema as compared to 59.52 % and 
52.38 % inhibition by 4 and 1 respectively in the case of anti-inflammatory activity. In the tail flick method, 
reaction time increased significantly for the test and standard groups when compared to the predrug reaction 
time. The test drug produced a dose dependent increase in the reaction time at various time intervals of 
observation. In comparison to ketoprofen, the test compound 5 was found to be considerably less ulcerogenic 
indicating that GI toxicity due to direct contact of the carboxylic group has been reduced. The results are 
mentioned in Table 1. 
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Table1: Comparative Chart of Prepared comps 5, 4 & Ketoprofen 1 
With respect to their m.p. and biological properties 
 
Compound 
 
Ketoprofen  4  5 
Melting Point 
 
96
0 112-114 C 
0 163-164 C 
0C 
Anti-inflammatory activity 
(%) 
52.38  59.52  64.28 
Analgesic activity (%) 
 
45.67  71.87  81.73 
% of Animals with ulcer 
 
100  66.66  33.33 
Ulcer Index 
 
6.0  4.0  1.5 
 
 